ECO ANIMAL HEALTH GROUP PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.5 GBX | +1.19% |
|
+2.63% | +16.58% |
| May. 08 | TRADING UPDATES: ECO hails vaccine results; Plant Health sales down | AN |
| Apr. 25 | EARNINGS AND TRADING: ECO Animal revenue up; Zephyr starts drilling | AN |
| Sales 2024 * | 89.47M 114M | Sales 2025 * | 92.65M 118M | Capitalization | 84.68M 108M |
|---|---|---|---|---|---|
| Net income 2024 * | 2M 2.54M | Net income 2025 * | 2M 2.54M | EV / Sales 2024 * | 0.73 x |
| Net cash position 2024 * | 19.44M 24.68M | Net cash position 2025 * | 18.17M 23.07M | EV / Sales 2025 * | 0.72 x |
| P/E ratio 2024 * |
54
x | P/E ratio 2025 * |
43.4
x | Employees | 234 |
| Yield 2024 * |
-
| Yield 2025 * |
0.56% | Free-Float | 83.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.19% | ||
| 1 week | +2.63% | ||
| Current month | +1.19% | ||
| 1 month | +12.44% | ||
| 3 months | +36.01% | ||
| 6 months | +16.58% | ||
| Current year | +16.58% |
1 week
118.00
131.00
1 month
110.00131.00
Current year
82.00131.00
1 year
82.00131.00
3 years
80.75390.00
5 years
80.75439.00
10 years
80.75685.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 22-03-31 | |
| Director of Finance/CFO | 60 | 19-09-02 | |
Jordi Mora
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Armstrong
BRD | Director/Board Member | 67 | 20-04-30 |
| Director of Finance/CFO | 60 | 19-09-02 | |
| Director/Board Member | 64 | Feb. 11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 126.5 | +1.19% | 1 581 |
| 24-05-31 | 125 | +2.04% | 152,802 |
| 24-05-30 | 122.5 | -4.48% | 98,072 |
| 24-05-29 | 128.2 | +4.06% | 17,899 |
| 24-05-28 | 123.2 | +4.45% | 122,447 |
Delayed Quote London S.E., June 03, 2024 at 03:00 am EDT
More quotes
ECO Animal Health Group plc is a United Kingdom-based animal health biotechnology company. The Company is engaged in the manufacturing and supplying of animal health products globally. The Company is focused on providing solutions to respiratory and enteric diseases in pigs and poultry. It provides quality products for swine and poultry, primarily anti-infectives. The Companyâs segment includes the United Kingdom, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World. The Company research, develops and commercializes products for livestock. The Companyâs lead product, Aivlosin, is an antimicrobial which is used under veterinary prescription for the treatment of economically important respiratory and gastrointestinal diseases in pigs and poultry. The Company is also engaged in researching and developing new solutions to enhance the lives of pigs and poultry.
Sector
Pharmaceuticals
Calendar
2024-06-30
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.25
GBP
Average target price
1.89
GBP
Spread / Average Target
+51.17%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +16.58% | 108M | |
| -14.09% | 77.37B | |
| +18.66% | 8.74B | |
| +23.75% | 3.67B | |
| -1.67% | 3.25B | |
| +18.24% | 1.73B | |
| -16.99% | 1.38B | |
| -0.39% | 1.31B | |
| -26.05% | 1.24B | |
| -17.86% | 1.07B |
- Stock Market
- Equities
- EAH Stock
